Scholarlink

Background <p>In advanced urothelial carcinoma (UC), the prognostic impact of metastatic site and burden during avelumab maintenance therapy remains poorly defined.</p> Methods <p>We performed a sub-analysis of the Italian multicenter retrospective–prospective observational study Meet-URO 25, including patients with advanced UC who received avelumab maintenance after disease control with first-line platinum-based chemotherapy. We assessed the association between metastatic site and number of metastatic sites at the start of avelumab and clinical outcomes, including objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).</p> Results <p>A total of 243 patients were included. Lymph nodes (79.0%), lungs (32.1%), and bones (27.2%) were the most common metastatic sites. The median number of metastatic sites at the start of avelumab maintenance was 1. ORR and disease control rate (DCR) were higher in patients with nodal-only disease (ORR 28.9%, DCR 69.4%) and significantly lower in those with bone metastases (ORR 9.8%, DCR 50.8%). Median PFS and OS were 7.4 and 24.1&#xa0;months, respectively, in the overall cohort. Bone metastases were associated with markedly shorter PFS (3.7 vs. 8.2&#xa0;months; HR 1.92, <i>p</i> &lt; 0.001) and OS (11.3 vs. 27.6&#xa0;months; HR 2.44, <i>p</i> &lt; 0.001), especially when present as a single metastatic site. Increasing number of metastatic sites was also associated with poorer outcomes (OS: 35.5&#xa0;months with one site vs. 11.9&#xa0;months with ≥ 3 sites; <i>p</i> &lt; 0.001).</p> Conclusions <p>In this real-world cohort, both metastatic site and burden strongly influenced response and survival of avelumab. Bone metastases were independently associated with poor prognosis, while nodal-only disease identified a favorable subgroup. These findings support risk-based treatment stratification in the maintenance setting.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Site and number of metastases predict outcomes in avelumab maintenance for advanced UC: results from meet-URO 25

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月14日

查看全文
  • Giandomenico Roviello,
  • Elisabetta Gambale,
  • Irene De Gennaro Aquino,
  • Marco Maruzzo,
  • Carlo Messina,
  • Ismaela Anna Vascotto,
  • Virginia Rossi,
  • Davide Bimbatti,
  • Elisa Erbetta,
  • Marco Messina,
  • Alessia Mennitto,
  • Sara Elena Rebuzzi,
  • Cecilia Nasso,
  • Chiara Mercinelli,
  • Martina Catalano,
  • Brigida Anna Maiorano,
  • Martina Fanelli,
  • Mariella Sorarù,
  • Federico Scolari,
  • Marinella Micol Mela,
  • Luca Galli,
  • Alessia Salfi,
  • Mimma Rizzo,
  • Silvia Puglisi,
  • Valentina Orlando,
  • Giuseppe Fornarini,
  • Alessandro Rametta,
  • Patrizia Giannatempo,
  • Linda Cerbone,
  • Laura Doni,
  • Serena Pillozzi,
  • Lorenzo Antonuzzo

摘要

Background

In advanced urothelial carcinoma (UC), the prognostic impact of metastatic site and burden during avelumab maintenance therapy remains poorly defined.

Methods

We performed a sub-analysis of the Italian multicenter retrospective–prospective observational study Meet-URO 25, including patients with advanced UC who received avelumab maintenance after disease control with first-line platinum-based chemotherapy. We assessed the association between metastatic site and number of metastatic sites at the start of avelumab and clinical outcomes, including objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).

Results

A total of 243 patients were included. Lymph nodes (79.0%), lungs (32.1%), and bones (27.2%) were the most common metastatic sites. The median number of metastatic sites at the start of avelumab maintenance was 1. ORR and disease control rate (DCR) were higher in patients with nodal-only disease (ORR 28.9%, DCR 69.4%) and significantly lower in those with bone metastases (ORR 9.8%, DCR 50.8%). Median PFS and OS were 7.4 and 24.1 months, respectively, in the overall cohort. Bone metastases were associated with markedly shorter PFS (3.7 vs. 8.2 months; HR 1.92, p < 0.001) and OS (11.3 vs. 27.6 months; HR 2.44, p < 0.001), especially when present as a single metastatic site. Increasing number of metastatic sites was also associated with poorer outcomes (OS: 35.5 months with one site vs. 11.9 months with ≥ 3 sites; p < 0.001).

Conclusions

In this real-world cohort, both metastatic site and burden strongly influenced response and survival of avelumab. Bone metastases were independently associated with poor prognosis, while nodal-only disease identified a favorable subgroup. These findings support risk-based treatment stratification in the maintenance setting.